In the kidney, epoxyeicosatrienoic acids (EETs) have been suggested to be endothelium-derived hyperpolarizing factors (EDHFs). The aim of the present study was to determine the contribution of EETs to the preglomerular vasodilation elicited by bradykinin. Sprague-Dawley rats were studied utilizing an in vitro perfused juxtamedullary nephron preparation. The afferent arteriolar diameter was determined and the diameter averaged 19 ± 1 µm (n = 26) at a renal perfusion pressure of 100 mm Hg. Addition of 1, 10 and 100 nM bradykinin to the perfusate dose-dependently increased afferent arteriolar diameter by 5 ± 1, 12 ± 2 and 17 ± 2%, respectively. The nitric oxide inhibitor Nω-nitro-L-arginine reduced bradykinin-induced afferent arteriolar vasodilation by 50%, and the diameter increased by 9 ± 2% in response to 100 nM bradykinin. Epoxygenase inhibitors N-methylsulphonyl-6-(2-propargyloxyphenyl)hexanamide or miconazole greatly attenuated the nitric oxide-independent component of the vasodilation elicited by bradykinin. Cyclooxygenase (COX) inhibition attenuated the nitric oxide-independent vasodilation elicited by 1 nM bradykinin but did not significantly affect the vascular response to 100 nM bradykinin. Combined inhibition of nitric oxide, COX and epoxygenase pathways completely abolished bradykinin-mediated afferent arteriolar vasodilation. In additional studies, renal microvessels were isolated and incubated with bradykinin and samples were analyzed by NICI/GC/MS. Under control conditions, renal microvascular EET levels averaged 49 ± 9 pg/mg/20 min (n = 7). In the presence of bradykinin, EET levels were significantly higher and averaged 81 ± 11 pg/mg/20 min (n = 7). These data support the concept that EETs are EDHFs and contribute to the nitric oxide-independent afferent arteriolar vasodilation elicited by bradykinin.

Keywords:
Bradykinin, Nitric oxide, Endothelium-derived hyperpolarizing factor, Cytochrome P450 metabolites, Epoxyeicosatrienoic acids, Prostaglandins, Kidney
1.
Rubanyi GM: The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22(suppl 4):S1–S14.
2.
Mombouli JV, Bissiriou I, Agboton V, Vanhoutte PM: Endothelium-derived hyperpolarizing factor: A key mediator of the vasodilator action of bradykinin. Immunopharmacology 1996;33:46–50.
3.
Campbell WB, Gebremedhin D, Pratt PF, Harder DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996;78:415–423.
4.
Harder DR, Lange AR, Gebremedhin D, Birks EK, Roman RJ: Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. J Vasc Res 1997;34:237–243.
5.
Gebremedhin D, Harder DR, Pratt PF, Campbell WB: Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: Role of a cytochrome P450 metabolite. J Vasc Res 1998;35:274–284.
6.
Fulton D, McGiff JC, Quilley J: Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat. Br J Pharmacol 1992;107:722–725.
7.
Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493–497.
8.
Tomioka H, Hattori Y, Fukao M, Sato A, Liu MY, Sakuma I, Kitabatake A, Kanno M: Relaxation in different-sized rat blood vessels mediated by endothelium-derived hyperpolarizing factor: Importance of processes mediating precontractions. J Vasc Res 1999;36:311–320.
9.
Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR: Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996;7:2364–2370.
10.
Imig JD, Falck JR, Inscho EW: Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br J Pharmacol 1999;127:1399–1405.
11.
Imig JD, Deichmann PC: Afferent arteriolar responses to angiotensin II involve activation of phospholipase A2 and modulation by lipoxygenase and cytochrome P450 pathways. Am J Physiol 1997;273:F274–F282.
12.
Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML: Cytochrome P450-derived arachidonic acid metabolism in rat kidney: Characterization of selective inhibitors. J Pharmacol Exp Ther 1998;284:966–973.
13.
Zou AP, Imig JD, Ortiz de Montellano PR, Sui Z, Roman RJ: Inhibition of renal vascular 20-HETE impairs autoregulation of renal blood flow. Am J Physiol 1994;266:F275–F282.
14.
Capdevila JH, Dishman E, Karara A, Falck JR: Cytochrome P450 arachidonic acid epoxygenase: Stereochemical characterization of epoxyeicosatrienoic acids. Methods Enzymol 1991;206:441–453.
15.
McGiff JC, Carroll MA, Escalante B: Arachidonate metabolites and kinins in blood pressure regulation. Hypertension 1991;18(5 suppl):III150–III157.
16.
Fulton D, Mahboubi K, McGiff JC, Quilley J: Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol 1995;114:99–102.
17.
Fulton D, McGiff JC, Quilley J: Pharmacological evaluation of an epoxide as the putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart. J Pharmacol Exp Ther 1998;287:497–503.
18.
Nishikawa Y, Stepp DW, Chilian WM: Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. Am J Physiol Heart Circ Physiol 2000;279:H459–H465.
19.
Rosolowsky M, Campbell WB: Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochim Biophys Acta 1996;1299:267–277.
20.
Karara A, Makita K, Jacobson HR, Falck JR, Guengerich FP, DuBois RN, Capdevila JH: Molecular cloning, expression and enzymatic characterization of the rat kidney cytochrome P-450 arachidonic acid epoxygenases. J Biol Chem 1993;268:13565–13570.
21.
Imig JD: Epoxyeicosatrienoic acids: Biosynthesis, regulation and actions. Methods Mol Biol 1999;120:173–192.
22.
Makita K, Falck JR, Capdevila JH: Cytochrome P450, the arachidonic acid cascade, and hypertension: New vistas for an old system. FASEB J 1996;10:1456–1463.
23.
Wang MH, Stec DE, Balazy M, Mastyugin V, Yang CS, Roman RJ, Schwartzman ML: Cloning, sequencing, and cDNA-directed expression of the rat renal CYP4A2:Arachidonic acid ω-hydroxylation and 11,12-epoxidation by CYP4A2 protein. Arch Biochem Biophys 1996;336:240–250.
24.
Takahashi K, Capdevila J, Karara A, Falck JR, Jacobson HR, Badr KF: Cytochrome P-450 arachidonate metabolites in rat kidney: Characterization and hemodynamic responses. Am J Physiol1990;258:F781–F789.
25.
Carroll MA, Balazy M, Margiotta P, Falck JR, McGiff JC: Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J Biol Chem 1993;268:12260–12266.
26.
Carroll MA, Schwartzman M, Capdevila J, Falck JR, McGiff JC: Vasoactivity of arachidonic acid epoxides. Eur J Pharmacol 1987;138:281–283.
27.
Imig JD, Inscho EW, Deichmann PC, Reddy KM, Falck JR: Afferent arteriolar vasodilation to the sulfonimide analog of 11,12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension 1999;33:408–413.
28.
Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, Roman RJ: Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K+-channel activity. Am J Physiol 1996;270:F822–F832.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.